The effect of gilt flow management during acclimation on Mycoplasma hyopneumoniae detection.
Acclimation
Gilt flow
Laryngeal swabs
Mycoplasma hyopneumoniae
Real-time PCR
Serology
Journal
Veterinary microbiology
ISSN: 1873-2542
Titre abrégé: Vet Microbiol
Pays: Netherlands
ID NLM: 7705469
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
received:
14
04
2022
revised:
03
08
2022
accepted:
31
08
2022
pubmed:
27
11
2022
medline:
28
12
2022
entrez:
26
11
2022
Statut:
ppublish
Résumé
The objective of this study was to characterize the Mycoplasma hyopneumoniae (M. hyopneumoniae) detection and seroconversion patterns in recently acclimated gilts to be introduced to endemically infected farms using different types of replacement management. Three gilt developing units (GDUs) belonging to sow farms were included in this investigation: two farms managed gilts in continuous flow, and one farm managed gilts all-in/all-out. Two replicates of 35 gilts each were selected per GDU and sampled approximately every 60 days for a total of four or five samplings, per replicate and per GDU. Detection of M. hyopneumoniae was evaluated by PCR, while antibodies were measured using a commercial ELISA assay. Also, M. hyopneumoniae genetic variability was evaluated using Multiple-Locus Variable number tandem repeat Analysis. Detection of M. hyopneumoniae was similar across GDUs. Although a significant proportion of gilts was detected positive for M. hyopneumoniae after acclimation, an average of 30.3 % of gilts was negative at any point during the study. Detection of M. hyopneumoniae antibodies was similar among GDUs regardless of flow type or vaccination protocol. The genetic variability analysis revealed a limited number of M. hyopneumoniae types within each GDU. Results of this study showed a similar pattern of M. hyopneumoniae detection by PCR and seroconversion by ELISA among GDUs, regardless of the type of flow management strategies applied to gilts.
Identifiants
pubmed: 36435011
pii: S0378-1135(22)00224-3
doi: 10.1016/j.vetmic.2022.109554
pii:
doi:
Substances chimiques
Antibodies, Bacterial
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
109554Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no competing interest. Dr. Fano is employed by Boehringer Ingelheim Animal Health, products from this company were used in pigs in this study. However, the objective of the study was not related to the evaluation of the effect of commercial products.